Table 1.
RT-QuIC seeding profiles stratified by diagnosis
| PD n = 235 |
DLB n = 49 |
p Value PD/DLB vs. controls | Controls n = 26 |
Asymptomatic mutation carriers n = 14 |
p Value asymptomatic mutation carriers vs. Controls |
|
|---|---|---|---|---|---|---|
| Male Sex % | 65 | 70 | 0.237 | 54 | 36 | 0.271 |
| Age (y) | 64 ± 9 | 72 ± 7*** | ≤ 0.001 | 59 ± 12 | 58 ± 15 | 0.855 |
| Age at onset (y) | 57 ± 10 | 68 ± 7*** | – | – | – | – |
| Disease duration (y) | 7 ± 6 | 3 ± 2*** | – | – | – | – |
| UPDRS III | 25 ± 11 | 30 ± 13* | ≤ 0.001 | 2 ± 2 | 1 ± 1 | 0.112 |
| MoCA | 25 ± 4 | 15 ± 6*** | ≤ 0.001 | 27 ± 3 | 28 ± 2 | 0.303 |
| LEDD | 544 ± 475 | 392 ± 216* | – | – | – | |
| RT-QuIC positive seeding n (%) | 200 (85) | 42 (86) | ≤ 0.001 | 2 (8) | 2 (14) | 0.516 |
| RT-QuIC 0/4 positive seeding n (%) | 35 (15) | 7 (14) | ≤ 0.001 | 18 (92) | 12 (86) | 0.363 |
| RT-QuIC 2/4 positive seeding n (%) | 18 (8) | 1 (2) | 1 (4) | 0 | ||
| RT-QuIC 3/4 positive seeding n (%) | 54 (23) | 12 (25) | 0 | 1 (7) | ||
| RT-QuIC 4/4 positive seeding n (%) | 128 (54) | 29 (59) | 1 (4) | 1 (7) | ||
| RT-QuIC AUC | 761 ± 239 | 804 ± 225 | – | – | – | – |
| RT-QuIC Imax | 70 ± 13 | 69 ± 12 | – | – | – | – |
| RT-QuIC LAG | 21 ± 3 | 20 ± 3 | – | – | – | – |
| CSF total alpha-synuclein pg/ml | 567 ± 262 | 535 ± 322* | 0.175 | 583 ± 181 | 627 ± 389 | 0.677 |
| CSF Aβ1–42 pg/ml | 713 ± 262 | 518 ± 229** | ≤ 0.001 | 925 ± 231 | 885 ± 407 | 0.693 |
| CSF t-Tau pg/ml | 242 ± 132 | 328 ± 238 | 0.151 | 240 ± 97 | 242 ± 120 | 0.955 |
| CSF p-Tau pg/ml | 41 ± 16 | 49 ± 28 | 0.429 | 41 ± 13 | 44 ± 17 | 0.561 |
| NFL pg/ml | 917 ± 850 | 1921 ± 1888*** | ≤ 0.001 | 542 ± 239 | 431 ± 91 | 0.294 |
MoCA montreal cognitive assessment, UPDRS III Unified Parkinson Disease Rating Scale part III, LEDD L-Dopa equivalent daily dose
p values were corrected for age and sex when compared to controls and age, age at onset and disease duration for comparison of PD vs. DLB where appropriate. Significance level PD vs. DLB: *p < 0.05, **p < 0.01, ***p ≤ 0.001